Ignite Creation Date:
2024-05-05 @ 11:48 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00133796
Status:
TERMINATED
Last Update Posted:
2017-02-07
First Post:
2005-08-22
Brief Title:
Neoadjuvant Herceptin in Patients With Breast Cancer
Sponsor:
Mothaffar Rimawi
Organization:
Baylor Breast Care Center
Study Overview
Official Title:
A Phase II Study of the Effects of Herceptin in Patients With Locally Advanced HER-2NEU Overexpressing Breast Cancer
Status:
TERMINATED
Status Verified Date:
2017-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Closed to accrual 4192006 Study doesnt qualify for reporting
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purposes of this study are to better understand how Herceptin causes tumors to become smaller and to find out how effective Herceptin together with chemotherapy is in treating advanced breast cancer
Detailed Description:
We want to determine the effects of Herceptin and to determine its efficacy in women with HER-2 overexpressing advanced breast cancer The end-points will include the comparison of an array of histologic and molecular markers from sequential core biopsies of primary breast cancers of patients receiving Herceptin
The other aim of this study would be to determine clinical response to therapy with Herceptin and Taxotere
The other aim of this study would be to determine clinical response to therapy with Herceptin and Taxotere
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None